Figure 1
From: Outcome of therapy-related myeloid neoplasms treated with azacitidine
Overall survival of 50 t-MN patients treated with azacitidine. Median survival was 25.6 months (range 1.1-61.1+) from initial diagnosis and 21 months (range 1–53.6+) from AZA start
